ReviewCell surface (Amsterdam, Netherlands)2021
Prospects for anti-
Review in Cell surface (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Compromising UDP-sugar nucleotide biosynthesis attenuatesCell surface (Amsterdam, Netherlands) · 2026Article
- Dynamics of 1,3-β-D-Glucan in Invasive Candidiasis: A Narrative Review of Microbiological Aspects and Diagnostic Implications.Antibodies (Basel, Switzerland) · 2026Review
- Nature-Derived Ferulic Acid Hybrids with Enhanced Antifungal and Antivirulence Activity AgainstInternational journal of molecular sciences · 2026Article
- Review
- Exploring fungal survival mechanisms: toward next-generation antifungal therapies against Candida spp.Archives of microbiology · 2025Review
- Synthesis and Antifungal Evaluation AgainstMicroorganisms · 2025Article
- Effective treatment of systemic candidiasis by synergistic targeting of cell wall synthesis.Nature communications · 2025Article
- Resilience in Resistance: The Role of Cell Wall Integrity in Multidrug-Resistant Candida.Journal of fungi (Basel, Switzerland) · 2025Review
- In vitro evaluation of silver-zinc oxide-eugenol nanocomposite for enhanced antimicrobial and wound healing applications in diabetic conditions.Discover nano · 2025Article
- Antimicrobial Efficacy of GS-2 on Reusable Food Packaging Materials for Specialty Crops.Foods (Basel, Switzerland) · 2024Article
- Antibacterial Properties of Copper Oxide Nanoparticles (Review).International journal of molecular sciences · 2024Review
- Antifungal resistance: why are we losing this battle?Future microbiology · 2024Review
- Transcriptional Reprogramming ofJournal of fungi (Basel, Switzerland) · 2023Article
- Antimicrobial Activity of Biogenic Metal Oxide Nanoparticles and Their Synergistic Effect on Clinical Pathogens.International journal of molecular sciences · 2023Article
- Article
- Associations of Rap1 with Cell Wall Integrity, Biofilm Formation, and Virulence in Candida albicans.Microbiology spectrum · 2022Article
- Vaccine development for pathogenic fungi: current status and future directions.Expert review of vaccinesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
The impact of fungal infections on humans is a serious public health issue that has received much less attention than bacterial infection and treatment, despite ever-increasing incidence exacerbated by an increased incidence of immunocompromised individuals in the population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.